“It should be protocol that 100% of your patients with metastatic prostate cancer get germline testing. Full stop. No exceptions,” said Neal D. Shore, MD, FACS.

In a secondary analysis of the DEPROMP trial, 94.8% of biopsy-naive men had no AEs immediately after multimodal MRI- and PSMA ...

Chih-Yi “Andy” Liao, MD, discusses the FDA approval of lirafugratinib and what the field has learned about resistance to FGFR2 inhibitors.

Estelamari Rodriguez, MD, MPH, of Sylvester Comprehensive Cancer Center presents the final overall survival data from the phase 3 FLAURA2 study of osimertinib plus chemotherapy in epidermal growth ...

In the phase 3 NRG-CC009 trial, SRS led to longer overall survival vs HA-WBRT plus memantine with similar neurocognitive failure in SCLC brain metastases.

Phase 2 ASPEN-06 data showed higher response rates with evorpacept added to trastuzumab, ramucirumab, and paclitaxel in ...

Ethan B. Ludmir, MD, explains the rationale for moving radiation into the neoadjuvant setting for borderline resectable ...

Hans C. Lee, MD, discussed how community oncologists with limited access to MRD testing can think about the new IMS/IMWG ...

Ola Landgren, MD, PhD, discusses how MRD-driven strategies may eliminate the transplant-eligible vs transplant-ineligible ...

“[W]e should strive to increase the [number] of patients…who enjoy long-term disease-free survival and possibly cure,” said Meletios Dimopoulos, MD. Meletios A. Dimopoulos, MD, explored how ...

Jyoti Malhotra, MD, MPH on first-in-human clinical trials, lung cancer precision medicine in 2026, the disparities tension in drug development, and her move to Yale Cancer Center. In this episode ...

No new safety signals were observed with the daratumumab regimen after an additional 3 years of follow-up in the phase 3 ...